By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Takeda Pharmaceuticals 

Takeda Pharmaceuticals U.S.A. Inc.
One Takeda Parkway
Deerfield  Illinois  60015  U.S.A.
Phone: 224-554-6500 Fax: n/a


Millennium Pharmaceuticals was established in 1993 as a genomics company, applying world-class molecular biology and genomic technologies to the discovery
and development of new therapies in a broad spectrum of diseases. Over time we evolved into a fully integrated biopharmaceutical company.

In May 2008, Millennium was acquired by Takeda Pharmaceutical Company Limited in Japan and became known as Millennium: The Takeda Oncology Company (Millennium), a wholly-owned subsidiary of Takeda that served as the organization’s global center of excellence in oncology.

The combination of oncology resources resulted in a robust pipeline that addresses a broad range of cancers. Our focus is to improve the treatment of cancer, which gives us an important oncology mission to deliver extraordinary medicines to patients with cancer worldwide through our science, innovation and passion, toward an ultimate goal and aspiration to cure cancer.

In May 2013, the decision was made to fully integrate Millennium into the global Takeda R&D engine to maximize the resources available from the broader Takeda organization and to realize greater operational efficiencies. The R&D and G&A functions in Boston became known publically as Takeda Pharmaceuticals International Co. The oncology Commercial, Business Development and Patient Advocacy divisions continue to operate as Millennium: The Takeda Oncology Company.

At Takeda and Millennium, we want to exceed expectations in terms of progress against cancer, distinguishing ourselves within the research-based biopharmaceutical community. We’re prepared to deliver on this goal by focusing on novel or best-in-class drug candidates, and cultivating the brightest talent. This puts Takeda on an exciting path toward global oncology leadership.

We help drive and accelerate the progress that continually is being made against cancer; these advances, sometimes big breakthroughs and sometimes incremental, make a real difference in the lives of patients. We won’t be satisfied until cures are found and the threat is removed. People who battle cancer deserve no less.

Our goal also is to provide patients and people close to them with easily understandable information about the diseases our products treat, as well as other relevant information and service resources. We also provide information about our investigational drugs that are approaching or in development, our clinical trials, and what patients, caregivers and healthcare providers need to know about our assistance and access programs for any drug we currently market. We work toward our goals with the same urgency for patients that we would for our families. We strive to earn the respect and admiration of the global oncology community by delivering significant progress against cancer while living our core values.

The people and culture at Takeda and Millennium make all the difference.

Our work is more than a job. We are entrepreneurial about both our work and achieving progress. We focus on what’s important and timely decision-making.

As a site based in New England, we enjoy our local community and contribute in many ways to local business, social and environmental causes. We offer a broad range of opportunities for campus-based employees to participate. We also involve ourselves on a corporate level in matters of social responsibility.

Key Statistics

Ownership: Subsidiary

Web Site: Takeda
Employees: 5,500+
Symbol: TKPYY


SmithKline Beecham 

Human Genome Sciences, Inc.  Human Gene Consortium Partners

Company News
Teva (TEVA) And Takeda (TKPYY) Establish Unique Partnership To Meet The Wide-Ranging Needs Of Patients And Growing Importance Of Generic Medicines Use In Japan 11/30/2015 1:31:03 PM
Adding Multimedia U.S. FDA Approves Takeda (TKPYY)’s Ninlaro(Ixazomib), The First And Only Oral Proteasome Inhibitor To Treat Multiple Myeloma 11/23/2015 12:20:30 PM
FDA Approves Takeda (TKPYY)'s Ixazomib for Multiple Myeloma 11/20/2015 11:14:49 AM
Takeda (TKPYY) Receives Back-To-Back Recognition, Named A 2015 Top Chicago Workplace 11/13/2015 10:28:30 AM
Takeda (TKPYY) To Present Data From Ixazomib’s Phase 3 Study In Relapsed/Refractory Multiple Myeloma At Upcoming American Society of Hematology Annual Meeting 11/5/2015 12:29:11 PM
Takeda (TKPYY) Reports Results For The First Half Of FY2015 Confirms Management Guidance For The Full Year 10/30/2015 9:18:53 AM
Seattle Genetics (SGEN) And Takeda (TKPYY) Achieve Target Enrollment In Phase III ECHELON-1 Clinical Trial Evaluating ADCETRIS (Brentuximab Vedotin) In Previously Untreated Advanced Hodgkin Lymphoma (HL) 10/27/2015 11:03:20 AM
Univercells SA Enters Strategic Partnership With Takeda (TKPYY) To Produce Affordable Vaccines For Developing Countries 10/23/2015 9:44:24 AM
Takeda (TKPYY) Presents Vedolizumab Data At The 2015 American College of Gastroenterology Annual Meeting 10/19/2015 10:44:47 AM
University College London And Takeda (TKPYY) Announce A New Research Partnership To Identify Novel Therapeutic Targets For Neurodegenerative Diseases 10/14/2015 1:33:19 PM